Commonwealth Laboratories, based in Salem, Mass., has launched IBSchek, a blood test designed to detect irritable bowel syndrome.
The new blood test identifies the presence of anti-CdtB and anti-vinculin, both of which are indicative of diarrhea-prominent IBS, within 24 hours. The study featuring this data was published in the peer-reviewed journal PLOS ONE.
"Data from this study validates our long-held suspicion that IBS is caused by infection, by way of confirming anti-vinculin and anti-CdtB as blood-based biomarkers that provide a differential diagnosis of IBS," said Mark Pimentel, MD, FRCPC, director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai in Los Angeles.